OBJECTIVES: To determine the effectiveness of enzyme replacement therapies (ERT) for adults with Gaucher disease (GD). DESIGN: A longitudinal, multi-centre cohort study, including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data. PARTICIPANTS: Consenting adults (N = 150, aged 16 to 83 years) with a diagnosis of GD who attended a specialist treatment centre in England. At recruitment, 131 patients were receiving ERT (mean treatment duration, 10.8 years; range 0-18 years). OUTCOME MEASURES: Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin; absence/presence of bone pain; spleen and liver volumes and AST levels. RESULTS: One hundred and fifty adults were recruited. Duration of ERT was associated with statistically significant improvements in platelet count (p < 0.001), haemoglobin (p < 0.001), liver and spleen volumes (p < 0.001) and AST levels (p = 0.02). CONCLUSIONS: These data provide further evidence of the long-term effectiveness of ERT in adults with GD.
OBJECTIVES: To determine the effectiveness of enzyme replacement therapies (ERT) for adults with Gaucher disease (GD). DESIGN: A longitudinal, multi-centre cohort study, including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data. PARTICIPANTS: Consenting adults (N = 150, aged 16 to 83 years) with a diagnosis of GD who attended a specialist treatment centre in England. At recruitment, 131 patients were receiving ERT (mean treatment duration, 10.8 years; range 0-18 years). OUTCOME MEASURES: Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin; absence/presence of bone pain; spleen and liver volumes and AST levels. RESULTS: One hundred and fifty adults were recruited. Duration of ERT was associated with statistically significant improvements in platelet count (p < 0.001), haemoglobin (p < 0.001), liver and spleen volumes (p < 0.001) and AST levels (p = 0.02). CONCLUSIONS: These data provide further evidence of the long-term effectiveness of ERT in adults with GD.
Authors: D I Rosenthal; J A Scott; J Barranger; H J Mankin; S Saini; T J Brady; L K Osier; S Doppelt Journal: J Bone Joint Surg Am Date: 1986-07 Impact factor: 5.284
Authors: Deborah Elstein; A Joseph Foldes; David Zahrieh; Gabriel M Cohn; Maja Djordjevic; Costin Brutaru; Ari Zimran Journal: Blood Cells Mol Dis Date: 2011-05-04 Impact factor: 3.039
Authors: N Tayebi; M Callahan; V Madike; B K Stubblefield; E Orvisky; D Krasnewich; J J Fillano; E Sidransky Journal: Mol Genet Metab Date: 2001-08 Impact factor: 4.797
Authors: Marieke Biegstraaten; Eugen Mengel; Laszlo Maródi; Milan Petakov; Claus Niederau; Pilar Giraldo; Derralyn Hughes; Mirando Mrsic; Atul Mehta; Carla E M Hollak; Ivo N van Schaik Journal: Brain Date: 2010-08-07 Impact factor: 13.501
Authors: G A Grabowski; N W Barton; G Pastores; J M Dambrosia; T K Banerjee; M A McKee; C Parker; R Schiffmann; S C Hill; R O Brady Journal: Ann Intern Med Date: 1995-01-01 Impact factor: 25.391
Authors: K Wyatt; W Henley; L Anderson; R Anderson; V Nikolaou; K Stein; L Klinger; D Hughes; S Waldek; R Lachmann; A Mehta; A Vellodi; S Logan Journal: Health Technol Assess Date: 2012 Impact factor: 4.014
Authors: L J Anderson; W Henley; K M Wyatt; V Nikolaou; S Waldek; D A Hughes; G M Pastores; S Logan Journal: J Inherit Metab Dis Date: 2014-03-18 Impact factor: 4.982
Authors: Michael L Ganz; Sean Stern; Alex Ward; Luba Nalysnyk; Martin Selzer; Alaa Hamed; Neal Weinreb Journal: Orphanet J Rare Dis Date: 2017-02-20 Impact factor: 4.123